AUTL

Autolus Therapeutics plc develops advanced autologous T cell therapies, focusing on Chimeric Antigen Receptor (CAR) technology to treat cancer and autoimmune diseases. The company is engaged in the research, development, and commercialization of its product candidates, including obe-cel for adult Acute Lymphoblastic Leukemia (ALL), and has a pipeline targeting both hematological malignancies and solid tumors. Autolus operates in the clinical-stage biotechnology sector, utilizing proprietary manufacturing processes to engineer T cells for therapeutic applications.